Navigation Links
Acute Pain Global Clinical Trials Review, H2, 2013
Date:11/27/2013

London (PRWEB) November 27, 2013

Acute Pain Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, “Acute Pain Global Clinical Trials Review, H2, 2013" provides data on the Acute Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

-Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
-Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

-Understand the dynamics of a particular indication in a condensed manner
-Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
-Obtain discontinued trial listing for trials across the globe
-Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Con
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
2. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
3. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
4. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)... 2015  Champions Oncology (OTC-BB: CSBR), a company engaged ... to personalize the development and use of oncology drugs, ... results for the fourth quarter and fiscal year quarter ... before market open. The company will host ... at 9:00 a.m. EDT (6:00 a.m. PDT). To participate ...
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
(Date:7/24/2015)... China , July 24, 2015 ... manufacturing platform , Expands product offering for chronic ... unmet medical needs in diabetes-related complications and dermatology ... 3SBio Inc., (HKEX:1530) ("3SBio" or ,the Company"), a leading ... researching, developing, manufacturing and marketing biopharmaceutical products, today announced ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4
... ( http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), ... China and the US, today announced that the,Company will ... New,York City on Tuesday, October 7, 2008 at 10:30 ... Hyatt New York Hotel in the Morosco Room., ...
... Proceeds to Support R&D Efforts and Clinical ... BETHESDA, Md., Oct. 3 Micromet, Inc. ... company developing,novel, proprietary antibodies for the treatment ... that it has closed its previously,announced $40 ...
... of Aberdeen and Rothamsted Research for releasing natural insect repellents that ... technology is set to revolutionise how people protect buildings from unwanted ... ... (PRWEB) October 3, 2008 -- Atrium Innovation Ltd has developed a ...
Cached Biology Technology:AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 2New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 3New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 4
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... the fields of social, biological and medical science will ... discuss how they can cooperate to improve our understanding ... how our genetic inheritance is expressed (epigenetics). This collaboration ... changes have for such key social policy issues as ...
... pharmaceutical companies and four research institutions, working with the ... partnership that aims to speed the discovery of essential ... known as the TB Drug Accelerator (TBDA), will target ... early-stage research. The long-term goal of the TBDA is ...
... is home to a teeming ecosystem of microbes that is ... while the gut microbiota is interacting with our body, they ... study published online in Genome Research , ... set of viruses associated with gut microbiota in global populations. ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 27 pharmaceutical companies join academic researchers to speed TB drug discovery 2Gut microbes battle a common set of viruses shared by global populations 2
...
... Clone/PAD: 3B8A10. ... to the C-terminal region ... Specificity: Specific for the ... Reactivity: Human (positive control: ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
...
Biology Products: